
BRAF V600E Antibody [clone V600E/1321] (V5229)


Catalog No.	Formulation	Size
V5229-100UG	0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced), 0.05% sodium azide	100 ug
V5229-20UG	0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced), 0.05% sodium azide	20 ug
V5229SAF-100UG	1 mg/ml in 1X PBS; BSA free, sodium azide free	100 ug

Bulk quote request

Availability	1-3 business days
Species Reactivity	Human
Format	Purified
Host	Mouse
Clonality	Monoclonal (mouse origin)
Isotype	Mouse IgG1, kappa
Clone Name	V600E/1321
Purity	Protein A/G affinity
UniProt	P15056
Localization	Cytoplasm
Applications	ELISA (Order BSA-free format for coating) Western blot: 2-4ug/ml
Limitations	This BRAF V600E antibody is available for research use only.



BRAF V600E Antibody Detection in Human Skeletal Muscle WB. Western blot analysis of human skeletal muscle tissue lysate using BRAF V600E Antibody clone V600E/1321. Immunoreactive bands are observed at approximately 40 kDa and 23 kDa.



SDS-PAGE analysis of purified, BSA-free BRAF V600E antibody (clone V600E/1321) as confirmation of integrity and purity.

Description

The BRAF gene encodes a cytoplasmic serine-threonine kinase, which initiates the activation of the mitogen-activated protein kinase (MAPK) signalling pathway. The oncogenic mutations in the kinase region of BRAF gene result in constitutive activation of the MAPK signalling pathway, leading to increased cell proliferation, resistance to apoptosis and tumor progression. The most common of all activating BRAF mutations leads to a substitution of valine (V) to glutamic acid (E) at the position 600 of the amino acid sequence. The BRAF V600E mutation is an important predictive and prognostic biomarker. The BRAF V600E mutation is detected in approximately 8% of all solid tumours, including 45% of papillary thyroid carcinomas, 40-60% of melanomas, 5-15% of colorectal adenocarcinomas, 35% of serous low grade and borderline ovarian carcinomas, 1-3% of non-small cell lung cancers, and 5-7% of cholangiocarcinomas. Furthermore, the BRAF V600E mutation is found in 100% of hairy cell leukaemia, 54% Erdheim-Chester disease, 38% of Langerhans cell histocytoses and 60% of pleomorphic xanthoastrocytomas.

For a recombinant monoclonal reagent with mutation-specific validation, see our BRAF V600E Antibody RM8 / BRAF V600E Mutation Antibody page.

Application Notes

Optimal dilution of the BRAF V600E antibody should be determined by the researcher.

Immunogen

An N-terminal KLH-conjugated peptide (amino acids 596-606, Cys-GLAT(E)KSRWSG) was used as the immunogen for the BRAF V600E antibody.

Storage

Aliquot the BRAF V600E antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.

Copyright © NSJ Bioreagents. All rights reserved.